| Figures/TablesFigures/Tables | ReferencesReferences
Summary
Background & aims
The study examined the value of n-3 LC-PUFA-enriched yogurt as means of improving cardiovascular health.
Design
Fifty three mildly hypertriacylglycerolemic subjects (TAG?¡Ý?1.7?mmol/L) participated in a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed 1) control yoghurt; 2) yoghurt enriched with 0.8?g n-3 LC-PUFA/d; or 3) yoghurt enriched with 3?g n-3 LC-PUFA/d for a period of 10?wks. Blood samples were taken at the beginning and the end of the study period.
Results
Following daily intake of 3?g n-3 LC-PUFA for 10 weeks, n-3 LC-PUFA levels increased significantly in plasma and red blood cells (RBC) with concomitant increase in the EPA-derived mediators (PGE3, 12-, 15-, 18-HEPE) in plasma whilst cardiovascular risk factors such as HDL, TAG, AA/EPA ratio, and n-3 index were improved (P?<?0.05); the decrease of TAG and increase in HDL were associated with the CD36 genotype.
Conclusion
The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators showing that daily consumption of n-3 PUFA enriched yoghurt can be an effective way of supplementing the daily diet and improving cardiovascular health.
Identifier:
()
